NCT00824512View on ClinicalTrials.gov

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia

PHASE2CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Friedreich Ataxia

Interventions

DRUG

EGb 761 120 mg

EGb 761® 120 mg bid, orally for 12 to 14 weeks

DRUG

Placebo

Placebo 1 tablet BID, orally for 12 to 14 weeks

Trial Locations (1)

75015

Hospital Necker Enfants Malades, Paris

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Ipsen

INDUSTRY